| Drug General Information |
| Drug ID |
D0PG5G
|
| Former ID |
DAP000107
|
| Drug Name |
Infliximab
|
| Synonyms |
Remicade (TN)
|
| Drug Type |
Antibody
|
| Indication |
Crohn's disease; Ulcerative colitis; Rheumatoid arthritis; Ankylosing spondylitis; Psoriatic arthritis; Plaque psoriasis [ICD10:K50.0, K51.90, M05.9, M45.3, L40.52, L40]
|
Approved |
[1],
[2],
[3]
|
|---|
|
Asthma [ICD10:J45]
|
Phase 3 |
[1],
[4]
|
|
Rheumatoid arthritis; Dermatomyositis; Polymyositis; Juvenile rheumatoid arthritis; Graft-versus-host disease; Esophagitis [ICD10:K20, L40, M05-M06, M08.0, T86.0]
|
Phase 2 |
[5],
[6],
[7],
[8],
[9],
[10],
[11],
[12],
[13],
[14]
|
| Therapeutic Class |
Immunosuppressive Agents
|
| Company |
Samsung Bioepsis
|
| Formula |
C6428H9912N1694O1987S46
|
| CAS Number |
CAS 170277-31-3
|
| SuperDrug ATC ID |
L04AB02
|
| Target and Pathway |
| Target(s) |
Tumor necrosis factor |
Target Info |
|
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
NF-kappa B signaling pathway
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
Apoptosis
|
|
TGF-beta signaling pathway
|
|
Osteoclast differentiation
|
|
Antigen processing and presentation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
Hematopoietic cell lineage
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Type I diabetes mellitus
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Pertussis
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
African trypanosomiasis
|
|
Malaria
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Influenza A
|
|
HTLV-I infection
|
|
Herpes simplex infection
|
|
Proteoglycans in cancer
|
|
Asthma
|
|
Inflammatory bowel disease (IBD)
|
|
Systemic lupus erythematosus
|
|
Rheumatoid arthritis
|
|
Allograft rejection
|
|
Graft-versus-host disease
|
|
Hypertrophic cardiomyopathy (HCM)
|
|
Dilated cardiomyopathy
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
Leptin Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
IL1 Signaling Pathway
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
Wnt signaling pathway
|
|
Pathway Interaction Database
|
IL27-mediated signaling events
|
|
Canonical NF-kappaB pathway
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Angiopoietin receptor Tie2-mediated signaling
|
|
Signaling events mediated by HDAC Class I
|
|
TNF receptor signaling pathway
|
|
Ceramide signaling pathway
|
|
amb2 Integrin signaling
|
|
RXR and RAR heterodimerization with other nuclear receptor
|
|
IL23-mediated signaling events
|
|
HIV-1 Nef: Negative effector of Fas and TNF-alpha
|
|
Caspase Cascade in Apoptosis
|
|
Cellular roles of Anthrax toxin
|
|
Downstream signaling in naï
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
Transcriptional regulation of white adipocyte differentiation
|
|
TNFR1-induced proapoptotic signaling
|
|
Regulation of TNFR1 signaling
|
|
TNFR1-induced NFkappaB signaling pathway
|
|
TNFR1-mediated ceramide production
|
|
TNFR2 non-canonical NF-kB pathway
|
|
TNF signaling
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
TGF Beta Signaling Pathway
|
|
Cytokines and Inflammatory Response
|
|
MAPK Signaling Pathway
|
|
EV release from cardiac cells and their functional effects
|
|
FAS pathway and Stress induction of HSP regulation
|
|
Apoptosis-related network due to altered Notch3 in ovarian cancer
|
|
Cardiac Hypertrophic Response
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Aryl Hydrocarbon Receptor
|
|
Apoptosis
|
|
Nanoparticle triggered regulated necrosis
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Adipogenesis
|
|
Allograft Rejection
|
|
TNF alpha Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Extrinsic Pathway for Apoptosis
|
|
Folate Metabolism
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
Regulation of toll-like receptor signaling pathway
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5004). |
|---|
| REF 2 | Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9. Epub 2008 Apr 15. |
|---|
| REF 3 | Drugs@FDA (Edaravone) |
|---|
| REF 4 | Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66. |
|---|
| REF 5 | ClinicalTrials.gov (NCT00006292) Infliximab for the Treatment of Early Rheumatoid Arthritis |
|---|
| REF 6 | ClinicalTrials.gov (NCT00029042) Infliximab to Treat Children With Juvenile Rheumatoid Arthritis |
|---|
| REF 7 | ClinicalTrials.gov (NCT00033891) Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis |
|---|
| REF 8 | ClinicalTrials.gov (NCT00076726) A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis |
|---|
| REF 9 | ClinicalTrials.gov (NCT00201799) Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation |
|---|
| REF 10 | ClinicalTrials.gov (NCT00230529) A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis |
|---|
| REF 11 | ClinicalTrials.gov (NCT00244192) Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia |
|---|
| REF 12 | ClinicalTrials.gov (NCT00443222) Treatment With TNF Blockade, Infliximab, in Patients With Myositis |
|---|
| REF 13 | ClinicalTrials.gov (NCT00523354) Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis |
|---|
| REF 14 | ClinicalTrials.gov (NCT00823641) The HAM Infliximab Study |
|---|
